Jonsson Comprehensive Cancer Center
🇺🇸United States
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Hormone-Resistant Prostate CancerStage IV Prostate CancerRecurrent Prostate CarcinomaMetastatic Prostate Carcinoma
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT02881242
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Phase 2
Completed
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- Biological: IpilimumabOther: Laboratory Biomarker AnalysisBiological: Nivolumab
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT02880020
- Locations
- 🇺🇸
Rachel Andes, Los Angeles, California, United States
Project Connect Online: An Internet-based Intervention for Women With Breast Cancer
Not Applicable
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Behavioral: Project Connect OnlineBehavioral: PCO PLUS
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT02866994
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT02851381
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Not Applicable
Completed
- Conditions
- Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7Stage II Prostate Adenocarcinoma AJCC v7Stage III Prostate Adenocarcinoma AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02830165
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
C11 Sodium Acetate PET/CT Imaging of PCa
- Conditions
- Prostate Cancer
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT02826395
- Locations
- 🇺🇸
200 Medical Plaza, B114, Los Angeles, California, United States
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
Not Applicable
Active, not recruiting
- Conditions
- Human Papillomavirus InfectionAnal CarcinomaHIV Infection
- Interventions
- Procedure: Cytology Specimen Collection ProcedureOther: Laboratory Biomarker Analysis
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 415
- Registration Number
- NCT02816879
- Locations
- 🇺🇸
Los Angeles Gay and Lesbian Center, Los Angeles, California, United States
🇺🇸Desert AIDS Project, Palm Springs, California, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Phase 1
Completed
- Conditions
- Childhood Solid NeoplasmAdult Solid NeoplasmMetastatic Neoplasm
- Interventions
- Biological: AldesleukinOther: Laboratory Biomarker AnalysisBiological: NivolumabBiological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBLBiological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell VaccineProcedure: Positron Emission Tomography
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02775292
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Phase 1
Withdrawn
- Conditions
- High Grade Fallopian Tube Serous AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaRecurrent Primary Peritoneal CarcinomaHigh Grade Ovarian Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT02756130
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Not Applicable
Recruiting
- Conditions
- Recurrent Adult Soft Tissue Sarcoma
- Interventions
- Procedure: Conventional SurgeryRadiation: Hypofractionated Radiation TherapyOther: Laboratory Biomarker AnalysisOther: Questionnaire Administration
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT02701153
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath